Fresenius SE & Co. KGaA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius SE & Co. KGaA
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
After withdrawing IPO plans last September, Elicio thinks merger with Angion will give it a cash runway through end of 2023 to advance ELI-002, a vaccine for mutant KRAS-driven solid tumors.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
- In Vitro Diagnostics
- Medical Devices
- Other Names / Subsidiaries
- APP Pharmaceuticals, Inc.
- Asia Renal Care Ltd.
- Fresenius Kabi Pharmaceuticals Holding, Inc.
- Fresenius Medical Care
- Fresenius Medical Group AG
- Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
- Xenios AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.